Generic Medicines Provide Savings for Maine Patients
Recently, the Portland Press-Herald newspaper published two opinion pieces – an editorial and an op-ed – that promote Making Health Care Work for Maine, a package of bills in the state legislature that would give the state government tremendous power over the prescription drug market. Unfortunately, the central arguments of both pieces are rooted in […]
A Roadmap for Access
We must secure sustainable markets to ensure patient access to generic and biosimilar medicines This article first appeared in The Medicine Maker on March 22, 2021. The COVID-19 global pandemic has presented a unique challenge to healthcare systems and infrastructure across the globe, including the generic drug supply chain. Generic drug manufacturers have met this […]
AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines
Association for Accessible Medicines Unveils Policy Agenda for Biden Administration and 117th Congress Outlines Policy Solutions to Support Long-Term Sustainability of Generic and Biosimilar Medicines New Campaign Highlights Lifesaving Role Generic Drugs Have Played in Treatment of COVID-19 Report Series Examines Threats to Patient Access and Affordability WASHINGTON, D.C. (FEBRUARY 22, 2021) – Today the […]
Cancer Costs and Options for Care in the United States
In 2020, cancer claimed the lives of 600,000 Americans. According to the American Cancer Society (ACS CAN), there are approximately 1.7 million new cases of cancer in the United States each year, and more than 16.9 million Americans have a cancer history. Today, on World Cancer Day, AAM and the Biosimilars Council pause to recognize […]
7 Policy Solutions
Association for Accessible Medicines is calling on Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter. To this end, we recommend these seven policy solutions: #Rx4Savings Campaign
AAM Statement on Trump’s Drug Pricing Ruling – Rebates and Most Favored Nation Model
WASHINGTON, DC (November 20, 2020) — AAM and its Biosimilars Council commend the Administration for today’s effort to remove perverse rebate incentives now blocking competition in the U.S. prescription drug marketplace, but further action is necessary to modernize the Medicare Part D program and ensure that patients and taxpayers realize the full value of lower […]
AAM Statement on Considered Expansion of Antitrust Lawsuit Against Generic Drugmakers
WASHINGTON, DC (October 31, 2017) – AAM and our member companies are committed to supporting policies that promote competition and help speed the availability of generic and biosimilar medicines to patients. AAM is fully committed to compliance with all laws and ethical business practices. Attribution: Jeff Francer, Senior Vice President and General Counsel MEDIA CONTACT: Rachel Schwartz 202.249.7147 (o) […]
Adding up the Generic Savings for Americans with Cancer and Other Conditions
Every year, the Association for Accessible Medicines (AAM) publishes a report demonstrating how much U.S. patients and our overall health care system save through the use of generic prescription drugs. As the newly released edition shows, the savings grow every year, totaling $313 billion in 2019 and close to $2.2 trillion over the past decade. […]
How to Talk About High Drug Costs in a Time of Economic Insecurity
Generic Drug Savings in the U.S.
In 2018 alone, generic prescription medicines saved the U.S. health care system $293 billion — and a whopping $2 trillion in the past 10 years. The availability of safe, effective and affordable generics produces tremendous savings for America’s patients. Some key figures: In 2018, 9 out of every 10 prescriptions in the U.S. were dispensed […]
Generic Drugs and Biosimilars Secure Big Savings for U.S. Patients
In 2019, generic medicines saved America’s patients $313 billion and nearly $2.2 trillion in the last decade. Biosimilar medicines also saved $2.2 billion and $4.5 billion over the past 10 years. The availability of safe, effective and affordable generics and biosimilars secures tremendous access and savings for America’s patients throughout the COVID-19 pandemic. Some key […]
Report: 2019 Generic Drug & Biosimilars Access & Savings in the U.S.
To view the latest data, view 2020 Access & Savings Report The American public is clamoring for systemic changes to address skyrocketing drug prices. Specialty drugs — a fast-growing category that includes biologics and other complex medicines — are of particular concern. These medicines account for only 2% of prescriptions but already represent almost half […]
